Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1990 May;49(5):331–336. doi: 10.1136/ard.49.5.331

Drug toxicity.

H A Bird 1
PMCID: PMC1004083  PMID: 2188624

Full text

PDF
331

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Habet S. M., Rogers H. J. Methylprednisolone pharmacokinetics after intravenous and oral administration. Br J Clin Pharmacol. 1989 Mar;27(3):285–290. doi: 10.1111/j.1365-2125.1989.tb05366.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ayesh R., Mitchell S. C., Waring R. H., Withrington R. H., Seifert M. H., Smith R. L. Sodium aurothiomalate toxicity and sulphoxidation capacity in rheumatoid arthritic patients. Br J Rheumatol. 1987 Jun;26(3):197–201. doi: 10.1093/rheumatology/26.3.197. [DOI] [PubMed] [Google Scholar]
  3. BEECHER H. K. The powerful placebo. J Am Med Assoc. 1955 Dec 24;159(17):1602–1606. doi: 10.1001/jama.1955.02960340022006. [DOI] [PubMed] [Google Scholar]
  4. Banerjee A. K. Enteropathy induced by non-steroidal anti-inflammatory drugs. BMJ. 1989 Jun 10;298(6687):1539–1540. doi: 10.1136/bmj.298.6687.1539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beaver W. T. Combination analgesics. Am J Med. 1984 Sep 10;77(3A):38–53. doi: 10.1016/s0002-9343(84)80101-1. [DOI] [PubMed] [Google Scholar]
  6. Bell C. L., Graziano F. M. The safety of administration of penicillamine to penicillin-sensitive individuals. Arthritis Rheum. 1983 Jun;26(6):801–803. doi: 10.1002/art.1780260617. [DOI] [PubMed] [Google Scholar]
  7. Bem J. L., Breckenridge A. M., Mann R. D., Rawlins M. D. Review of yellow cards (1986): report to the Committee on the Safety of Medicines. Br J Clin Pharmacol. 1988 Dec;26(6):679–689. doi: 10.1111/j.1365-2125.1988.tb05305.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bird H. A., Dixon J. S., Finney P. L., Leatham P. A., Lowe J. R., Pickup M. E., Rhind V. M., Rushton A., Sitton N. G., Wright V. A clinical and biochemical evaluation of Clozic, a novel disease modifying drug in rheumatoid arthritis. Clin Exp Rheumatol. 1983 Apr-Jun;1(2):93–99. [PubMed] [Google Scholar]
  9. Bird H. A. Rheumatology and the pharmaceutical industry. J Rheumatol. 1983 Aug;10(4):663–664. [PubMed] [Google Scholar]
  10. Bird H. A., Ring E. F., Bacon P. A. A thermographic and clinical comparison of three intra-articular steroid preparations in rheumatoid arthritis. Ann Rheum Dis. 1979 Feb;38(1):36–39. doi: 10.1136/ard.38.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bird H. A. The kidney in rheumatic diseases. Ann Rheum Dis. 1989 Dec;48(12):1029–1030. doi: 10.1136/ard.48.12.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bird H. A., Yu H., Cooper E. H. Renal proximal dysfunction in patients with rheumatic diseases. Br Med J (Clin Res Ed) 1984 Apr 7;288(6423):1044–1045. doi: 10.1136/bmj.288.6423.1044-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Blodgett R. C., Jr, Heuer M. A., Pietrusko R. G. Auranofin: a unique oral chrysotherapeutic agent. Semin Arthritis Rheum. 1984 Feb;13(3):255–273. doi: 10.1016/0049-0172(84)90029-5. [DOI] [PubMed] [Google Scholar]
  14. Brooks P. M., Miners J. O., Smith K., Smith M. D., Fearnley I., Birkett D. J. Dose, plasma concentration and response relationships of D-penicillamine in patients with rheumatoid arthritis. J Rheumatol. 1984 Dec;11(6):772–775. [PubMed] [Google Scholar]
  15. Buckingham R. B. Interactions involving antirheumatic agents. Part I. Bull Rheum Dis. 1977;28(8):960–965. [PubMed] [Google Scholar]
  16. Buckingham R. B. Interactions involving antirheumatic agents. Part II. Bull Rheum Dis. 1977;28(9):966–971. [PubMed] [Google Scholar]
  17. Clinch D., Banerjee A. K., Levy D. W., Ostick G., Faragher E. B. Non-steroidal anti-inflammatory drugs and peptic ulceration. J R Coll Physicians Lond. 1987 Jul;21(3):183–187. [PMC free article] [PubMed] [Google Scholar]
  18. Collier D. S., Pain J. A. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut. 1985 Apr;26(4):359–363. doi: 10.1136/gut.26.4.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Collins A. J., Du Toit J. A. Upper gastrointestinal findings and faecal occult blood in patients with rheumatic diseases taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol. 1987 Aug;26(4):295–298. doi: 10.1093/rheumatology/26.4.295. [DOI] [PubMed] [Google Scholar]
  20. Cove-Smith J. R., Knapp M. S. Analgesic nephropathy: an important cause of chronic renal failure. Q J Med. 1978 Jan;47(185):49–69. [PubMed] [Google Scholar]
  21. Dawson M., McGee C. M., Vine J. H., Nash P., Watson T. R., Brooks P. M. The disposition of biphenylacetic acid following topical application. Eur J Clin Pharmacol. 1988;33(6):639–642. doi: 10.1007/BF00542502. [DOI] [PubMed] [Google Scholar]
  22. Day R. O., Brooks P. M. Variations in response to non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol. 1987 Jun;23(6):655–658. doi: 10.1111/j.1365-2125.1987.tb03098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dixon J. S., Bojar R., Bird H. A. Renal impairment in relation to non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 1988 Mar;47(3):260–260. doi: 10.1136/ard.47.3.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Doherty M., Hunt R. H., Langman M. J., Pounder R. E., Russell R. I., Sturrock R. D., Thould A. K. Management of NSAID induced gastrointestinal disturbance. Ann Rheum Dis. 1987 Aug;46(8):640–643. doi: 10.1136/ard.46.8.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Dougados M., Duchesne L., Awada H., Amor B. Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis. 1989 Jul;48(7):550–556. doi: 10.1136/ard.48.7.550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med. 1988 Oct 14;85(4A):23–29. doi: 10.1016/0002-9343(88)90358-0. [DOI] [PubMed] [Google Scholar]
  27. Farah D., Sturrock R. D., Russell R. I. Peptic ulcer in rheumatoid arthritis. Ann Rheum Dis. 1988 Jun;47(6):478–480. doi: 10.1136/ard.47.6.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Favre L., Glasson P., Riondel A., Vallotton M. B. Interaction of diuretics and non-steroidal anti-inflammatory drugs in man. Clin Sci (Lond) 1983 Apr;64(4):407–415. doi: 10.1042/cs0640407. [DOI] [PubMed] [Google Scholar]
  29. Furst D. E., Kremer J. M. Methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):305–314. doi: 10.1002/art.1780310301. [DOI] [PubMed] [Google Scholar]
  30. Furst D. E., Levine S., Srinivasan R., Metzger A. L., Bangert R., Paulus H. E. A double-blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis. Arthritis Rheum. 1977 Nov-Dec;20(8):1473–1480. doi: 10.1002/art.1780200805. [DOI] [PubMed] [Google Scholar]
  31. Gabriel R. Time to scrap creatinine clearance? Br Med J (Clin Res Ed) 1986 Nov 1;293(6555):1119–1120. doi: 10.1136/bmj.293.6555.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Girdwood R. H. Death after taking medicaments. Br Med J. 1974 Mar 16;1(5906):501–504. doi: 10.1136/bmj.1.5906.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Gispen J. G., Alarcón G. S., Johnson J. J., Acton R. T., Barger B. O., Koopman W. J. Toxicity of methotrexate in rheumatoid arthritis. J Rheumatol. 1987 Feb;14(1):74–79. [PubMed] [Google Scholar]
  34. Grennan D. M., Ferry D. G., Ashworth M. E., Kenny R. E., Mackinnon M. The aspirin-ibuprofen interaction in rheumatoid arthritis. Br J Clin Pharmacol. 1979 Nov;8(5):497–503. doi: 10.1111/j.1365-2125.1979.tb01033.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Griffin J. P. Post-marketing surveillance of licensed medicinal and other products. Health Trends. 1981 Aug;13(3):85–88. [PubMed] [Google Scholar]
  36. Grindulis K. A., McConkey B. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone. Ann Rheum Dis. 1984 Jun;43(3):398–401. doi: 10.1136/ard.43.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Hampton J. R., Julian D. G. Role of the pharmaceutical industry in major clinical trials. Lancet. 1987 Nov 28;2(8570):1258–1259. doi: 10.1016/s0140-6736(87)91863-0. [DOI] [PubMed] [Google Scholar]
  38. Heath M. J. Measurement of 'free' gold in patients receiving disodium aurothiomalate and the association of high free to total gold levels with toxicity. Ann Rheum Dis. 1988 Jan;47(1):18–21. doi: 10.1136/ard.47.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Heath M. J., Swannell A. J., Williams C. R., Palmer T. Patterns of urinary excretion of gold in patients with rheumatoid arthritis undergoing chrysotherapy. Ann Rheum Dis. 1987 Nov;46(11):823–826. doi: 10.1136/ard.46.11.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Hemming J. D., Bird H. A., Pickup M. E., Saunders A., Lowe J. R., Dixon J. S. Bioavailability of aspirin in the presence of dextropropoxyphene/paracetamol combination. Pharmatherapeutica. 1981;2(8):543–546. [PubMed] [Google Scholar]
  41. Inman W. H., Rawson N. S., Wilton L. V., Pearce G. L., Speirs C. J. Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring. BMJ. 1988 Oct 1;297(6652):826–829. doi: 10.1136/bmj.297.6652.826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Jick S. S., Perera D. R., Walker A. M., Jick H. Non-steroidal anti-inflammatory drugs and hospital admission for perforated peptic ulcer. Lancet. 1987 Aug 15;2(8555):380–382. doi: 10.1016/s0140-6736(87)92393-2. [DOI] [PubMed] [Google Scholar]
  43. Kaiser D. G., Glenn E. M. Aspirin-ibuprofen interaction in the adjuvant-induced polyarthritic rat. Res Commun Chem Pathol Pharmacol. 1974 Nov;9(3):583–586. [PubMed] [Google Scholar]
  44. Kincaid-Smith P. Analgesic nephropathy. Br Med J (Clin Res Ed) 1981 May 30;282(6278):1790–1791. doi: 10.1136/bmj.282.6278.1790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Koopmans P. P., Thien T., Gribnau F. W. Influence of non-steroidal anti-inflammatory drugs on diuretic treatment of mild to moderate essential hypertension. Br Med J (Clin Res Ed) 1984 Dec 1;289(6457):1492–1494. doi: 10.1136/bmj.289.6457.1492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Loebl D. H., Craig R. M., Culic D. D., Ridolfo A. S., Falk J., Schmid F. R. Gastrointestinal blood loss. Effect of aspirin, fenoprofen, and acetaminophen in rheumatoid arthritis as determined by sequential gastroscopy and radioactive fecal markers. JAMA. 1977 Mar 7;237(10):976–981. doi: 10.1001/jama.237.10.976. [DOI] [PubMed] [Google Scholar]
  47. Madhok R., Capell H. A., Waring R. Does sulphoxidation state predict gold toxicity in rheumatoid arthritis? Br Med J (Clin Res Ed) 1987 Feb 21;294(6570):483–483. doi: 10.1136/bmj.294.6570.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Mills J. A. Rheumatology and the pharmaceutical industry. J Rheumatol. 1983 Aug;10(4):531–532. [PubMed] [Google Scholar]
  49. Needs C. J., Brooks P. M. Antirheumatic medication in pregnancy. Br J Rheumatol. 1985 Aug;24(3):282–290. doi: 10.1093/rheumatology/24.3.282. [DOI] [PubMed] [Google Scholar]
  50. Panayi G. S., Huston G., Shah R. R., Mitchell S. C., Idle J. R., Smith R. L., Waring R. H. Deficient sulphoxidation status and D-penicillamine toxicity. Lancet. 1983 Feb 19;1(8321):414–414. doi: 10.1016/s0140-6736(83)91526-x. [DOI] [PubMed] [Google Scholar]
  51. Passmore A. P., Copeland S., Johnston G. D. A comparison of the effects of ibuprofen and indomethacin upon renal haemodynamics and electrolyte excretion in the presence and absence of frusemide. Br J Clin Pharmacol. 1989 Apr;27(4):483–490. doi: 10.1111/j.1365-2125.1989.tb05397.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Perrier P., Raffoux C., Thomas P., Tamisier J. N., Busson M., Gaucher A., Streiff F. HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis. Ann Rheum Dis. 1985 Sep;44(9):621–624. doi: 10.1136/ard.44.9.621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Pullar T., Hunter J. A., Capell H. A. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis. 1985 Dec;44(12):831–837. doi: 10.1136/ard.44.12.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rawlins M. D. Postmarketing surveillance of adverse reactions to drugs. Br Med J (Clin Res Ed) 1984 Mar 24;288(6421):879–880. doi: 10.1136/bmj.288.6421.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Rawlins M. D. Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol. 1988 Jul;26(1):1–5. doi: 10.1111/j.1365-2125.1988.tb03356.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Role of the pharmaceutical industry in major clinical trials. Lancet. 1987 Dec 19;2(8573):1464–1465. [PubMed] [Google Scholar]
  57. Semble E. L., Wu W. C. Antiinflammatory drugs and gastric mucosal damage. Semin Arthritis Rheum. 1987 May;16(4):271–286. doi: 10.1016/0049-0172(87)90005-9. [DOI] [PubMed] [Google Scholar]
  58. Shipley M. E., Bacon P. A., Berry H., Hazleman B. L., Sturrock R. D., Swinson D. R., Williams I. A. Pulsed methylprednisolone in active early rheumatoid disease: a dose-ranging study. Br J Rheumatol. 1988 Jun;27(3):211–214. doi: 10.1093/rheumatology/27.3.211. [DOI] [PubMed] [Google Scholar]
  59. Skander M. P., Ryan F. P. Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly. BMJ. 1988 Oct 1;297(6652):833–834. doi: 10.1136/bmj.297.6652.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Skeith M. D., Simkin P. A., Healey L. A. The renal excretion of indomethacin and its inhibition by probenecid. Clin Pharmacol Ther. 1968 Jan-Feb;9(1):89–93. doi: 10.1002/cpt19689189. [DOI] [PubMed] [Google Scholar]
  61. Smith M. D., Ahern M. J., Roberts-Thomson P. J. Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone? Ann Rheum Dis. 1988 Jan;47(1):28–33. doi: 10.1136/ard.47.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Smith P. J., Swinburn W. R., Swinson D. R., Stewart I. M. Influence of previous gold toxicity on subsequent development of penicillamine toxicity. 1982 Aug 28-Sep 4Br Med J (Clin Res Ed) 285(6342):595–596. doi: 10.1136/bmj.285.6342.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Stastny P. Rheumatoid arthritis: relationship with HLA-D. Am J Med. 1983 Dec 30;75(6A):9–15. doi: 10.1016/0002-9343(83)90470-9. [DOI] [PubMed] [Google Scholar]
  64. Swainson C. P., Griffiths P. Acute and chronic effects of sulindac on renal function in chronic renal disease. Clin Pharmacol Ther. 1985 Mar;37(3):298–300. doi: 10.1038/clpt.1985.43. [DOI] [PubMed] [Google Scholar]
  65. Swainson C. P., Griffiths P., Watson M. L. Chronic effects of oral sulindac on renal haemodynamics and hormones in subjects with chronic renal disease. Clin Sci (Lond) 1986 Mar;70(3):243–247. doi: 10.1042/cs0700243. [DOI] [PubMed] [Google Scholar]
  66. Taggart A. J., McDermott B., Delargy M., Elborn S., Forbes J., Roberts S. D., Ahnfelt N. O. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis. Scand J Rheumatol Suppl. 1987;64:29–36. doi: 10.3109/03009748709096719. [DOI] [PubMed] [Google Scholar]
  67. Tishler M., Caspi D., Rosenbach T. O., Fishel B., Wigler I., Segal R., Gazit E., Yaron M. Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations. Ann Rheum Dis. 1988 Aug;47(8):654–659. doi: 10.1136/ard.47.8.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Tonkin A. L., Wing L. M. Interactions of non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol. 1988 Aug;2(2):455–483. doi: 10.1016/s0950-3579(88)80022-0. [DOI] [PubMed] [Google Scholar]
  69. Unsworth J., Sturman S., Lunec J., Blake D. R. Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 1987 Mar;46(3):233–236. doi: 10.1136/ard.46.3.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Volans G. N. Monitoring the safety of over the counter drugs. Br Med J (Clin Res Ed) 1987 Oct 3;295(6602):797–798. doi: 10.1136/bmj.295.6602.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Watkinson G. Sulphasalazine: a review of 40 years' experience. Drugs. 1986;32 (Suppl 1):1–11. doi: 10.2165/00003495-198600321-00003. [DOI] [PubMed] [Google Scholar]
  72. Wong D. G., Spence J. D., Lamki L., Freeman D., McDonald J. W. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet. 1986 May 3;1(8488):997–1001. doi: 10.1016/s0140-6736(86)91271-7. [DOI] [PubMed] [Google Scholar]
  73. Wooley P. H., Griffin J., Panayi G. S., Batchelor J. R., Welsh K. I., Gibson T. J. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980 Aug 7;303(6):300–302. doi: 10.1056/NEJM198008073030602. [DOI] [PubMed] [Google Scholar]
  74. Wrong O. Acid-base effects of "non-systemic" antacids. Lancet. 1986 Aug 23;2(8504):462–463. doi: 10.1016/s0140-6736(86)92171-9. [DOI] [PubMed] [Google Scholar]
  75. van Rijthoven A. W., Dijkmans B. A., Goei The H. S., Hermans J., Montnor-Beckers Z. L., Jacobs P. C., Cats A. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis. 1986 Sep;45(9):726–731. doi: 10.1136/ard.45.9.726. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES